3) Consortium TFF. A candidate gene for familial Mediterranean fever. Nat Genet 1997 ; 17 : 25-31.
6) Denman AM, Fialkow PJ, Pelton BK, Salo AC, Appleford DJ, Gilchrist C. Lymphocyte abnormalities in Behcet's syndrome. Clin Exp Immunol 1980 ; 42 : 175-85.
8) Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, et al. Oral health is impaired in Behcet's disease and is associated with disease severity. Rheumatology (Oxford) 2004 ; 43 : 1028-33.
9) Celenligil-Nazliel H, Kansu E, Ebersole JL. Periodontal findings and systemic antibody responses to oral microorganisms in Behcet's disease. J Periodontol 1999 ; 70 : 1449-56.
10) Umit K, Gonca M, Ismail S, Salih P, Osman K, Hakan E, et al. The close association between dental and periodontal treatments and oral ulcer course in Behcet's disease : a prospective clinical study. J Oral Pathol Med 2009 ; 38 : 410-5.
13) Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celic I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. Arthritis Rheum 1996 ; 39 : 2062-5.
14) Isogai E, Isogai H, Yokota K, Oguma K, Kimura K, Kubota T, et al. Experimental model for Behcet's disease in gnotobiotic mice infected with Streptococcus sanguis. In : Behcet's desease. Bang E, Lee ES, Lee S, eds. Design Mecca Publishing Co., Korea. 2001 : 133-8.
17) The Behcet's Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease : a multicenter study. J Rheumatol 1989 ; 16 : 506-11.
20) Sohn S, Lee ES, Bang D, Lee S. Behcet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol 1998 ; 8 : 21-3.
23) Yokota K, Hayashi S, Araki Y, Isogai E, Kotake S, Yoshikawa K. Characterization of Streptococcus sanguis isolated from patients with Behcet's disease. Microbiol Immunol 1995 ; 39 : 729-32.
29) Hamzaoui K, Hamzaoui A, Hentati F, Kahan A, Ayed K, Chabbou A, et al. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behcet's disease. J Rheumatol 1994 ; 21 : 2301-6.
30) Freysdottir J, Hussain L, Farmer I, Lau SH, Fortune F. Diversity of γδ T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis 2006 ; 12 : 271-7.
35) Carletto A, Pacor ML, Biasi D, Caramaschi P, Zeminian S, Bellavite P, et al. Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet's disease. J Rheumatol 1997 ; 24 : 1332-6.
37) Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet's disease. Clin Exp Rheumatol 2001 ; 19 (5 Suppl. 24) : S19-24.
38) Ureten K, Ertenli I, Ozturk MA, Kiraz S, Onat AM, Tuncer M, et al. Neutrophil CD64 expression in Behcet's disease. J Rheumatol 2005 ; 32 : 849-52.
42) Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993 ; 20 : 1544-9.
43) Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease : high levels may indicate vascular involvement. Int J Dermatol 2009 ; 48 : 259-64.
45) Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behcet's disease. J Rheumatol 1990 ; 17 : 1428-9.
54) Aktas Cetin E, Cosan F, Cefle A, Deniz G. IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behcet's disease. Mod Rheumatol 2014 ; 24 : 802-7.
55) Shimizu J, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behcet's disease. Clin Exp Immunol 2012 ; 168 : 68-74.
56) Na SY, Park MJ, Park S, Lee ES. Up-regulation of Th17 and related cytokines in Behcet's disease corresponding to disease activity. Clin Exp Rheumatol 2013 ; 31 : 32-40.
58) Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A. Expression of Th-17 and RORγt mRNA in Behcet's Disease. Med Sci Monit 2011 ; 17 : CR227-34.
60) Fortune F, Walker J, Lehner T. The expression of γδ T cell receptor and the prevalence of primed, activated and IgA-bound T cells in Behcet's syndrome. Clin Exp Immunol 1990 ; 82 : 326-32.
63) Parlakgul G, Guney E, Erer B, Kihcaslan Z, Direskeneli H, Gul A, et al. Expression of regulatory receptors on γδ T cells and their cytokine production in Behcet's disease. Arthritis Res Ther 2013 ; 15 : R15.
65) Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behcet's disease. Clin Exp Immunol 1988 ; 71 : 126-31.
66) Kibaroglu A, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behcet's disease. Clin Exp Rheumatol 2004 ; 22 : S59-63.
70) Poulter LW, Lehner T. Immunohistology of oral lesions from patients with recurrent oral ulcers and Behcet's syndrome. Clin Exp Immunol 1989 ; 78 : 189-95.
72) Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoglu T. Monocyte activity in Behcet's disease. Br J Rheumatol 1996 ; 35 : 424-9.
75) Castrichini M, Lazzerini PE, Gamberucci A, Capecchi PL, Franceschini R, Natale M, et al. The purinergic P2×7 receptor is expressed on monocytes in Behcet's disease and is modulated by TNF-α. Eur J Immunol 2014 ; 44 : 227-38.
81) Liang L, Tan X, Zhou Q, Zhu Y, Tian Y, Yu H, et al. IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behcet's disease. Invest Ophthalmol Vis Sci 2013 ; 54 : 402-14.
89) Inanc N, Mumcu G, Birtas E, Elbir Y, Yavuz S, Ergun T, et al. Serum mannose-binding lectin levels are decreased in behcet's disease and associated with disease severity. J Rheumatol 2005 ; 32 : 287-291.
90) Mumcu G, Inanc N, Aydin SZ, Ergun T. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behcet's disease. Clin Exp Rheumatol 2009 ; 27 (Suppl. 53) : S32-6.
91) Kim J, Im CH, Kang EH, Lee EY, Lee YJ, Park KS. Mannose-binding lectin gene-2 polymorphisms and serum mannose-binding lectin levels in Behcet's disease. Clin Exp Rheumatol 2009 ; 27 (Suppl. 53) : S13-7.
94) Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behcet's disease : correlations with disease activity and severity. Isr J Med Sci 1995 ; 31 : 345-8.
107) Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 2011 ; 34 : 755-68.
114) Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behcet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003 ; 21 (4 suppl. 30) : S35-7.
118) Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980 ; 65 : 399-402.
119) Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-92.
123) Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R. Successful use of canakinumab in a patient with resistant Behcet's disease. Clin Exp Rheumatol 2012 ; 30 : S115.
125) Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease : an open-label pilot study. Ann Rheum Dis 2012 ; 71 : 563-6.